Media headlines about Aileron Therapeutics (NASDAQ:ALRN) have trended somewhat positive recently, Accern Sentiment Analysis reports. The research group rates the sentiment of media coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Aileron Therapeutics earned a coverage optimism score of 0.08 on Accern’s scale. Accern also assigned media headlines about the company an impact score of 46.0348133367479 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
Several brokerages recently issued reports on ALRN. Bank of America Corporation began coverage on Aileron Therapeutics in a report on Monday, July 24th. They issued a “buy” rating and a $19.00 price target for the company. Jefferies Group LLC began coverage on Aileron Therapeutics in a report on Monday, July 24th. They issued a “buy” rating and a $20.00 price target for the company. Canaccord Genuity reiterated a “buy” rating and issued a $19.00 price target on shares of Aileron Therapeutics in a report on Friday, August 11th. Finally, William Blair began coverage on Aileron Therapeutics in a report on Monday, July 24th. They issued an “outperform” rating for the company.
Shares of Aileron Therapeutics (NASDAQ ALRN) traded down 2.89% during mid-day trading on Friday, reaching $14.09. The company had a trading volume of 336 shares. Aileron Therapeutics has a 52-week low of $10.37 and a 52-week high of $15.48. The stock’s market capitalization is $207.33 million. The company’s 50-day moving average is $12.87 and its 200 day moving average is $12.75.
COPYRIGHT VIOLATION WARNING: “Aileron Therapeutics (ALRN) Getting Somewhat Favorable Press Coverage, Analysis Finds” was first reported by Markets Daily and is owned by of Markets Daily. If you are accessing this story on another site, it was illegally copied and reposted in violation of United States & international copyright and trademark laws. The original version of this story can be accessed at https://www.themarketsdaily.com/2017/10/13/aileron-therapeutics-alrn-getting-somewhat-favorable-press-coverage-analysis-finds.html.
Aileron Therapeutics Company Profile
Aileron Therapeutics, Inc is a United States-based clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing a class of therapeutics called stapled peptides. It is also developing a pipeline of stapled peptide drugs across a range of therapeutic areas, including cancer, endocrine and metabolic diseases and inflammation.
Receive News & Ratings for Aileron Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aileron Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.